Schneider P, Goldbaum D, Agarwal A, Taylor A, Sundberg P, Gardner E
Pharmacol Biochem Behav. 2024; 247:173931.
PMID: 39626795
PMC: 11769769.
DOI: 10.1016/j.pbb.2024.173931.
Groenink L, Verdouw P, Zhao Y, Ter Heegde F, Wever K, Bijlsma E
Psychopharmacology (Berl). 2023; 240(11):2361-2401.
PMID: 36651922
PMC: 10593622.
DOI: 10.1007/s00213-022-06307-1.
Gozzi A, Lepore S, Vicentini E, Merlo-Pich E, Bifone A
Neuropsychopharmacology. 2013; 38(11):2120-30.
PMID: 23736277
PMC: 3773661.
DOI: 10.1038/npp.2013.109.
Zorrilla E, Heilig M, de Wit H, Shaham Y
Drug Alcohol Depend. 2013; 128(3):175-86.
PMID: 23294766
PMC: 3596012.
DOI: 10.1016/j.drugalcdep.2012.12.017.
Zorrilla E, Koob G
Drug Discov Today. 2010; 15(9-10):371-83.
PMID: 20206287
PMC: 2864802.
DOI: 10.1016/j.drudis.2010.02.011.
CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis.
Lowery E, Spanos M, Navarro M, Lyons A, Hodge C, Thiele T
Neuropsychopharmacology. 2010; 35(6):1241-52.
PMID: 20130533
PMC: 2927867.
DOI: 10.1038/npp.2009.209.
Allosteric modulators of class B G-protein-coupled receptors.
Hoare S
Curr Neuropharmacol. 2009; 5(3):168-79.
PMID: 19305799
PMC: 2656815.
DOI: 10.2174/157015907781695928.
Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures.
Sparta D, Sparrow A, Lowery E, Fee J, Knapp D, Thiele T
Alcohol Clin Exp Res. 2007; 32(2):259-65.
PMID: 18162072
PMC: 2274906.
DOI: 10.1111/j.1530-0277.2007.00575.x.
Corticotropin releasing factor-1 receptor antagonist, CP-154,526, blocks the expression of ethanol-induced behavioral sensitization in DBA/2J mice.
Fee J, Sparta D, Picker M, Thiele T
Neuroscience. 2007; 150(1):14-21.
PMID: 17919825
PMC: 2194653.
DOI: 10.1016/j.neuroscience.2007.08.027.
Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes.
Sahuque L, Kullberg E, McGeehan A, Kinder J, Hicks M, Blanton M
Psychopharmacology (Berl). 2006; 186(1):122-32.
PMID: 16568282
PMC: 1473306.
DOI: 10.1007/s00213-006-0362-y.
The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
Li Y, Fitzgerald L, Wong H, Lelas S, Zhang G, Lindner M
CNS Drug Rev. 2005; 11(1):21-52.
PMID: 15867951
PMC: 6741745.
DOI: 10.1111/j.1527-3458.2005.tb00034.x.
The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.
Seymour P, Schmidt A, Schulz D
CNS Drug Rev. 2003; 9(1):57-96.
PMID: 12595912
PMC: 6741649.
DOI: 10.1111/j.1527-3458.2003.tb00244.x.
Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I.
Pedersen W, Wan R, Zhang P, Mattson M
J Neurosci. 2002; 22(2):404-12.
PMID: 11784785
PMC: 6758668.
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
Habib K, Weld K, Rice K, Pushkas J, Champoux M, Listwak S
Proc Natl Acad Sci U S A. 2000; 97(11):6079-84.
PMID: 10823952
PMC: 18561.
DOI: 10.1073/pnas.97.11.6079.
Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH.
Weninger S, Dunn A, Muglia L, Dikkes P, Miczek K, Swiergiel A
Proc Natl Acad Sci U S A. 1999; 96(14):8283-8.
PMID: 10393986
PMC: 22226.
DOI: 10.1073/pnas.96.14.8283.
The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats.
Erb S, Shaham Y, Stewart J
J Neurosci. 1998; 18(14):5529-36.
PMID: 9651233
PMC: 6793509.
